New combo therapy shows promise for Tough-to-Treat kidney cancer
Disease control
Completed
This study tested whether adding an immunotherapy drug (nivolumab) to a targeted therapy (tivozanib) helps people with advanced kidney cancer whose disease worsened after prior treatment, including immunotherapy. The trial enrolled 343 adults and compared the combination against …
Phase: PHASE3 • Sponsor: AVEO Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 17, 2026 06:48 UTC